| Document Date: 2014-07-16 01:09:12
Open Document File Size: 1,85 MBShare Result on Facebook
City Rochester / / Company AEs / MerckSerono SA / Pfizer / / Continent Europe / / Country United States / United Kingdom / / Event FDA Phase / Product Issues / / Facility Imperial College / Mario Negri Institute / / IndustryTerm pharmaceutical product / biotechnology products / medicinal products / psoriasis treatment / important patient utilities / treatment of the disease / / MedicalCondition auto-immune diseases / Post-marketing surveillance RCT Randomized Controlled Trial Serious Infections Infections / neoplasms / POTENTIAL RISKS IN PSORIASIS PATIENTS / interstitial pneumonitis / inflammatory polyradiculoneuropathies / Bells palsy / severe psoriasis / lymphoma / inflammatory polyradiculoneuropathy / headache / facial palsy / severe immune deficiency / neurological disorders / erythroderma / arthritis / mild psoriasis / thrombocytopenia / hemolytic anemia / post-marketing safety experience Aseptic meningitis A / solid tumors / plaque psoriasis / lymphoproliferative disease / Thrombocytopenia / Leukocytosis / severe plaque psoriasis / injury / chronic inflammation / chronic recurring condition / encephalopathy / progressive multifocal leukoencephalopathy / polyradiculoneuropathy / multiple sclerosis / Viral meningitis / erythema multiforme / disorder / Fisher-Miller syndrome / severe chronic plaque psoriasis / interstitial lung diseases / psoriasis / severe infections / infections / protozoan infections / psoriatic arthritis / aseptic meningitis / cancers / congestive heart failure / hypertension / opportunistic infections / disease / PSORIASIS DISEASE / Guillain-Barre syndrome / stroke / diabetes / lymphocytosis / erythema / Itching / EPIDEMIOLOGY OF THE DISEASE / self-reported psoriasis / pain / opportunistic infection / rickettsia infections / autoimmune disease / encephalitis / AIDS / chronic diseases / pustular psoriasis / infection / significant depression / inflammation / depression / chronic recurrent nature / syndrome / immune hemolytic anemia / inflammatory / tuberculosis / usually fatal viral disease / / MedicalTreatment chemotherapy / biological therapies / vaccinations / self-care / / Organization Imperial College London / Mario Negri Institute / Task Force / European Medicines Agency / European Union / / Person Arch Dermatol / Larry Phillips Alain Micaleff / David Luciani / Nan Wang / Diana Hughes / Alain Micaleff / Kimberley Hockley / Lawrence Phillips / / Position Physician / Executive / / Product Ketek / cyclosporine / Raptiva / Tysabri / signals / Tysabri® (natalizumab) / / ProvinceOrState Minnesota / / RadioStation Wave 1 / / SportsEvent NHL / / Technology antibodies / biotechnology / chemotherapy / / URL www.imi.europa.eu / www.imiprotect.eu / /
SocialTag |
Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Report 1:b:iii Benefit - Risk Wave 1 Case Study Report: Raptiva® (efalizumab)